MCL
65 programs · 61 companies
Programs
65
Companies
61
Trials
59
MOAs
41
CDK4/6iFXIaiPCSK9iMeniniKIF18AiCDK2iAnti-AβSOS1iMALT1iBCL-2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Phase 1/2 | BET | ||
| MRK-3745 | Phase 2 | WRN | ||
| Ribofutibatinib | Phase 2/3 | SOS1 | ||
| AZN-4015 | Preclinical | BCMA | ||
| NVO-2974 | NDA/BLA | PARP | ||
| TAK-1836 | Preclinical | EGFR | ||
| Mavuglumide | Approved | GLP-1R | ||
| Zenotinib | Phase 1 | CGRP | ||
| Cevisacituzumab | Preclinical | MALT1 | ||
| Sovarelsin | Phase 2/3 | LAG-3 | ||
| Capifutibatinib | Phase 3 | PCSK9 | ||
| ION-3857 | Preclinical | Nectin-4 | ||
| Bemasotorasib | Phase 2 | CD38 | ||
| SND-4562 | NDA/BLA | AuroraA | ||
| Lisorapivir | Approved | AuroraA | ||
| Polazanubrutinib | Phase 1 | IL-17A | ||
| TSH-7567 | Phase 1/2 | WRN | ||
| Rilurelsin | Phase 1/2 | SOS1 | ||
| BVN-7642 | Phase 2 | CFTR | ||
| Fixarapivir | Preclinical | CD3 | ||
| Sotoratamab | Phase 2 | GLP-1R | ||
| CUV-6674 | Phase 1/2 | IL-23 | ||
| EVT-1993 | Phase 1/2 | BCL-2 | ||
| TEM-4581 | Phase 2/3 | CGRP | ||
| Teratenlimab | Approved | EGFR | ||
| JOH-IIT-632 | NDA/BLA | IL-17A | ||
| Zoribrutinib | Phase 1/2 | DLL3 | ||
| Gelitenlimab | Preclinical | EGFR | ||
| MET-3015 | Preclinical | MET | ||
| Tixanaritide | Phase 2/3 | AuroraA | ||
| Olpafotisoran | Phase 2 | IL-13 | ||
| Voxavorutinib | Phase 3 | CD123 | ||
| Sovaosocimab | Phase 1 | PRMT5 | ||
| Tirasotorasib | Approved | CFTR | ||
| Kemamavacamten | Preclinical | AHR | ||
| Tirazasiran | Phase 1/2 | BET | ||
| DER-1141 | Preclinical | FcRn | ||
| 300-2164 | Phase 3 | CD38 | ||
| 151-9555 | Phase 2/3 | B7-H3 | ||
| KAR-4449 | Phase 2 | MET | ||
| Lisosotorasib | Phase 3 | CFTR | ||
| DUK-IIT-640 | NDA/BLA | TIM-3 | ||
| Rimasacituzumab | Phase 2 | FcRn | ||
| HOM-3477 | Approved | PSMA | ||
| Mavuzanubrutinib | Phase 1/2 | IL-17A | ||
| Pexavorutinib | Preclinical | GIP-R | ||
| Motaratamab | Phase 2/3 | MDM2 | ||
| BWA-1517 | Approved | Aβ | ||
| Geliglumide | Phase 2/3 | TIM-3 | ||
| TOL-8761 | Phase 2 | EGFR | ||
| GRF-2905 | Phase 1 | Menin | ||
| Talaosocimab | Phase 1 | RET | ||
| Kemalucimab | Phase 2/3 | CGRP | ||
| WES-IIT-873 | Phase 2/3 | VEGF | ||
| RAB-IIT-267 | Approved | Nectin-4 | ||
| Surainavolisib | NDA/BLA | TYK2 | ||
| CYB-1519 | Phase 2/3 | GLP-1R | ||
| Doxatenlimab | Phase 2 | KRASG12C | ||
| Polacapivasertib | Approved | JAK1 | ||
| Olpazumab | Phase 1/2 | EGFR | ||
| ANG-3408 | Phase 2/3 | BCL-2 | ||
| Ribozumab | Phase 1/2 | JAK2 | ||
| Nidarelsin | Phase 2/3 | C5 | ||
| Sovalemzoparlimab | Phase 3 | GPRC5D | ||
| PAT-6991 | Phase 1/2 | CDK2 |
Trials (59)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04234271 | PFE-5767 | Phase 1/2 | Terminated |
| NCT04861455 | PFE-5767 | Phase 1/2 | Completed |
| NCT04054049 | NVO-2974 | NDA/BLA | Recruiting |
| NCT08099138 | Mavuglumide | Approved | Completed |
| NCT03866311 | Mavuglumide | Approved | Active |
| NCT03233804 | Mavuglumide | Approved | Active |
| NCT07864790 | Zenotinib | Phase 1 | Recruiting |
| NCT05305024 | Cevisacituzumab | Preclinical | Terminated |
| NCT07445911 | Cevisacituzumab | Preclinical | Active |
| NCT06305441 | Sovarelsin | Phase 2/3 | Not yet recr... |
| NCT03875492 | Capifutibatinib | Phase 3 | Terminated |
| NCT05365974 | Capifutibatinib | Phase 3 | Completed |
| NCT04268706 | ION-3857 | Preclinical | Not yet recr... |
| NCT06820996 | Bemasotorasib | Phase 2 | Recruiting |
| NCT06224445 | SND-4562 | NDA/BLA | Recruiting |
| NCT05655947 | Lisorapivir | Approved | Not yet recr... |
| NCT04027615 | TSH-7567 | Phase 1/2 | Completed |
| NCT08667743 | Rilurelsin | Phase 1/2 | Not yet recr... |
| NCT03075619 | BVN-7642 | Phase 2 | Active |
| NCT03995995 | Sotoratamab | Phase 2 | Not yet recr... |